Bicara Therapeutics announced its Q3 2026 financial results and progress on its lead cancer drug, ficerafusp alfa, targeting HPV-negative head and neck cancer. The company achieved substantial enrollment in its pivotal FORTIFI-HN01 trial and expects topline interim results by mid-2027. It is also conducting the FORTIFI-FLEX dosing study with data anticipated by potential U.S. approval. Bicara reported a net loss of $71.2 million for Q3, increased R&D and administrative expenses, and holds $442.3 million in cash and securities, funding operations into 2029. Upcoming milestones include data presentations in early 2027 and continued trial progress.
Bicara Therapeutics' Q3 2026 financial results and business update provide context for health-sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 18:41 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 108 rose and 26 fell today. Notable movers include INO (Inovio Pharmaceuticals Inc) at USD 1.36 with a 1-day change of +11.93% and a typical hold time of 41 days, FLNA (Cassava Sciences Inc) at USD 0.48 with +6.01%, and LFST (LifeStance Health Group Inc.) at USD 12.99 with -5.66% and a typical hold time of 12 days.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
